Compare Globus Medical Inc. Class A Common Stock (GMED) vs Halliburton Company (HAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Halliburton Company — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Halliburton Company trades at $33.06 (market cap $27.32B). The key difference: Halliburton Company is far larger — about 2.7× Globus Medical Inc. Class A Common Stock's market cap, and Halliburton Company pays a 2.07% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Halliburton Company for 89 Days on average.
| GMED | HAL | |
|---|---|---|
Market Cap | $10.25B | $27.32B |
Volume | 1,108,124 | 5,347,556 |
Sector | Health | Energy |
52-Week High | $96.82 | $42.98 |
52-Week Low | $58.33 | $21.82 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $9.76B | $33.47B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Halliburton (HAL) trades at $32.83, up 0.71% with a bearish technical signal despite recent earnings beats. The company shows solid fundamentals with a P/E of 17.17 and ROE of 14.89%, though 2025 net income declined to $1.28B from $2.5B in 2024. Recent developments include Venezuela energy agreements and a Cyprus deepwater contract win, positioning for international growth amid volatile oil markets.
Wall Street maintains strong bullish sentiment with 73% buy ratings and a $43.11 price target, representing 31% upside. Key risks include oil price volatility and execution challenges in new markets. The stock offers value with reasonable valuation metrics but faces near-term headwinds from declining profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →
